semaglutide and kidney failure FLOW clinical Trial (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes chronic kidney disease compared to placebo. Investigators Recent medical milestones include the

BackgroundObesity is a major public health issue associated with significant humanistic and economic burden

Today we announced positive topline results from the first Phase 1b clinical trial of elecoglipron conducted in China in adults living with obesity/overweight, with or without type 2 diabetes

This suggests that no dose adjustments should be required when semaglutide is administered concomitantly with these medications.

Diabetes mellitus, a condition that significantly elevates the incidence and mortality risks associated with cardiovascular diseases, exacerbates the disease burden in China

15,000

Obesity and associated complications can be managed by obesity medications, prompting the revision of criteria for the diagnosis and staging of this disease.